Bexarotene in combination with PUVA may be a treatment option in patients with cutaneous T-cell lymphoma refractory to multiple single-agent therapies

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1467, 2004-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Panobinostat is promising for the treatment of patients with cutaneous T-cell lymphoma

By  

Inpharma, Vol. 1, Iss. 1653, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Interferon (IFN)- plus bexarotene were effective in the treatment of multi focal, cutaneous, CD30+, large T cell lymphoma

By  

Inpharma, Vol. 1, Iss. 1324, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature

By Quéreux Gaëlle  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 13, 2013-09 ,pp. : 1711-1721

Informa Healthcare

Access to resources Recommend Favorite

Management of cutaneous T-cell lymphoma

By Duhovic Chris   Child Fiona   Wain E Mary  

Clinical Medicine, Vol. 12, Iss. 2, 2012-04 ,pp. : 160-164

Royal College Of Physicians

Access to resources Recommend Favorite

Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma

By Lansigan Frederick  

Drugs, Vol. 70, Iss. 3, 2010-02 ,pp. : 273-286

Adis International

Access to resources Recommend Favorite